On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.

The rally was driven by a recent RBC Capital Markets report highlighting that Illumina is building sustained clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can achieve durable mid-teens growth, primarily driven by oncology testing volume increases and easing pricing headwinds. The firm maintains an Outperform rating with a $230 price target. RBC noted that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.

The broader Life Sciences Tools and Services sector provided additional support, with Tempus AI up 10.02%, Personalis up 7.05%, Danaher up 3.29%, and Thermo Fisher Scientific up 2.31%, reflecting strong industry-wide momentum in genomics and precision medicine names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)